Literature DB >> 10214542

Interpreting research on prenatal substance exposure in the context of multiple confounding factors.

L L LaGasse1, R Seifer, B M Lester.   

Abstract

Fetal exposure to specific drugs often occurs in the context of polydrug use, medical complications, and social/environmental risks. Early reports of severe developmental consequences of fetal exposure to illicit drugs, for example, cocaine, have largely been unsupported by recent studies that take these factors into account. Using a database of published studies on cocaine exposure, this article examines how confounding factors are controlled by recruitment and statistical strategies. Rather than attempting to reduce the impact of these factors, it is suggested that multiple risks in children's lives should be included in models of developmental outcomes along with drug exposure. Understanding the complexity of multiple risks in the child's environment and the subtlety of drug exposure effects can guide the choice of clinical treatment and intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214542

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  13 in total

1.  Substance use during pregnancy: time for policy to catch up with research.

Authors:  Barry M Lester; Lynne Andreozzi; Lindsey Appiah
Journal:  Harm Reduct J       Date:  2004-04-20

2.  Prenatal cocaine use and maternal depression: effects on infant neurobehavior.

Authors:  Amy L Salisbury; Barry M Lester; Ronald Seifer; Linda Lagasse; Charles R Bauer; Seetha Shankaran; Henrietta Bada; Linda Wright; Jing Liu; Ken Poole
Journal:  Neurotoxicol Teratol       Date:  2006-12-14       Impact factor: 3.763

3.  Pre-placement risk and longitudinal cognitive development for children adopted from foster care.

Authors:  Jill M Waterman; Erum Nadeem; Emilie Paczkowski; Jared Cory Foster; Justin A Lavner; Thomas Belin; Jeanne Miranda
Journal:  Child Welfare       Date:  2013

4.  Deviant ERP response to spoken non-words among adolescents exposed to cocaine in utero.

Authors:  Nicole Landi; Michael J Crowley; Jia Wu; Christopher A Bailey; Linda C Mayes
Journal:  Brain Lang       Date:  2011-10-05       Impact factor: 2.381

5.  Reactivity and regulation of motor responses in cocaine-exposed infants.

Authors:  Melissa Duncan Fallone; Linda L LaGasse; Barry M Lester; Seetha Shankaran; Henrietta S Bada; Charles R Bauer
Journal:  Neurotoxicol Teratol       Date:  2014-02-28       Impact factor: 3.763

6.  Cumulative environmental risk in substance abusing women: early intervention, parenting stress, child abuse potential and child development.

Authors:  Susan J Kelley
Journal:  Child Abuse Negl       Date:  2003-09

7.  Prenatal drug exposure and maternal and infant feeding behaviour.

Authors:  L L LaGasse; D Messinger; B M Lester; R Seifer; E Z Tronick; C R Bauer; S Shankaran; H S Bada; L L Wright; V L Smeriglio; L P Finnegan; P L Maza; J Liu
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

8.  The effect of parenting stress on child behavior problems in high-risk children with prenatal drug exposure.

Authors:  Daniel M Bagner; Stephen J Sheinkopf; Cynthia Miller-Loncar; Linda L LaGasse; Barry M Lester; Jing Liu; Charles R Bauer; Seetha Shankaran; Henrietta Bada; Abhik Das
Journal:  Child Psychiatry Hum Dev       Date:  2008-07-15

9.  Children with and without gestational cocaine exposure: a neurocognitive systems analysis.

Authors:  Hallam Hurt; Laura M Betancourt; Elsa K Malmud; David M Shera; Joan M Giannetta; Nancy L Brodsky; Martha J Farah
Journal:  Neurotoxicol Teratol       Date:  2009-08-15       Impact factor: 3.763

10.  Protective factors can mitigate behavior problems after prenatal cocaine and other drug exposures.

Authors:  Henrietta S Bada; Carla M Bann; Toni M Whitaker; Charles R Bauer; Seetha Shankaran; Linda Lagasse; Barry M Lester; Jane Hammond; Rosemary Higgins
Journal:  Pediatrics       Date:  2012-11-26       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.